Which is better synflorix or Prevnar 13?
Which is better synflorix or Prevnar 13?
The pneumococcal conjugate vaccine is safe. In most cases, it does not cause any reactions. The Synflorix® vaccine generally causes slightly fewer reactions than the Prevnar 13® vaccine.
Who makes synflorix?
GlaxoSmithKline (GSK) today received European Commission authorisation for Synflorix™, a paediatric pneumococcal vaccine to protect against life-threatening diseases such as meningitis and bacteraemic pneumonia, as well as middle ear infections.
What is PCV10 vaccine?
PCV10, 10-valent pneumococcal conjugate vaccine. Protects against pneumococcal disease caused by at least 10 types of Streptococcus pneumoniae.
Is Prevnar 13 better than Pneumovax 23?
The main difference between Pneumovax 23 and Prevnar 13 is how many different types of bacteria they target. Pneumovax 23 protects against 23 types of pneumococcal bacteria and is used in adults, while Prevnar 13 protects against 13 types of pneumococcal bacteria, and was designed primarily for children.
What is Synflorix vaccine for?
Synflorix is a vaccine that protects against infections caused by S. pneumoniae. Vaccines work by ‘teaching’ the immune system (the body’s natural defences) to defend the body against the infection.
How do you inject Synflorix vaccine?
Use of Synflorix and other pneumococcal conjugate vaccines The vaccine should be given by intramuscular injection. The preferred sites are anterolateral aspect of the thigh in infants or the deltoid muscle of the upper arm in young children.
Which one is better PCV10 or PCV13?
The sample size provided 98% power for an overall conclusion on the difference between two doses of PCV10 and PCV13, and more than 99% power for an overall conclusion on the non-inferiority of two doses of PCV13 compared with three doses of PCV10.
Which is better PCV10 or PCV13?
Conclusion. Both PCV10 and PCV13 were immunogenic and induced a booster response. Compared to the PCV10 group, the PCV13 group showed higher levels for serotype 19F GMCs and avidity, pre- as well as post-booster, although opsonophagocytosis did not differ significantly between groups.
https://www.youtube.com/watch?v=POt3rxd3ti8
